Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
CERo Therapeutics, Inc. is a new cellular immunotherapy company.
AIRNA develops RNA editing technologies to create medicines for various diseases.
Arbor Biotechnologies is a biotechnology company specializing in next-generation gene editing therapeutics to treat genetic diseases.
Genetix Biotherapeutics develops and delivers approved gene therapies for severe rare genetic diseases like sickle cell.
Homeward is focused on improving access to high-quality, affordable primary and specialty care in rural communities.
Be Biopharma develops engineered B cell medicines for serious genetic diseases.
Rhygaze develops a novel gene therapy that targets cone cells to restore vision in patients suffering from diseases causing blindness.
Tenvie Therapeutics is a biotechnology company that transforms the treatment of neurological diseases through engineered small molecules.
Soufflé Therapeutics has potent, precise, and safe medicines can be designed and developed for all diseases.
Generate Biomedicines is a biotech company that combines biology, machine learning, and biological engineering to create biomedicines.
Akamis Bio is a clinical-stage oncology company.
Metsera is a clinical‐stage biotech firm developing oral & injectable hormone therapies to treat obesity & related metabolic diseases.
City Therapeutics is a biopharmaceutical company focused on developing next-generation small interfering RNAs.
EGenesis is a gene editing and genome engineering company developing human-compatible engineered organs to treat diseases.
ArsenalBio is a programmable cell therapy company that offers CAR T-cell therapies for solid tumors.
Ultivue is a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing.
Clinical stage biotechnology company developing restorative treatments for people affected by neuropsychiatric & neuroimmunologic disorders
Moleculent is the Biotechnology Research company.
Advanced Medicine Partners is a biotechnology company that specializes in viral vector manufacturing for genes and cells.
Vilya is a biotechnology company developing a novel class of drugs that precisely target the biology of disease.
Quantum Circuits is delivering a full-stack quantum computer based on the innovative dual-rail qubit providing superior performance.
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Neumora Therapeutics operates as a clinical-stage biotechnology company.
Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence.
ARCH Venture Partners has invested in 237 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
ARCH Venture Partners's top investment sectors include Biotechnology, Medical, Health Care, Therapeutics, Life Science. The firm invests across 20 different industry categories.
Among tracked funding rounds, Xaira Therapeutics received $1.0B in a Series A round. ARCH Venture Partners's total known invested capital is $27.3B.
ARCH Venture Partners's average investment size is $138.5M across its portfolio of 237 companies.
Recent ARCH Venture Partners portfolio additions include Cero Therapeutics, AIRNA, Arbor Biotechnologies, Genetix Biotherapeutics Inc., Homeward. These companies were founded in 2020 or later.